Off-the-Shelf immune cell therapy tested for tough lymphoma cases
NCT ID NCT06256484
Summary
This early-stage study tested the safety and initial effectiveness of ATA3219, a new type of 'off-the-shelf' immune cell therapy, for adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatments. The therapy involves collecting and modifying a donor's immune cells to target the cancer, then infusing them into the patient. The main goal was to find a safe dose and watch for side effects, while also checking if the treatment showed any signs of shrinking the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Cancer Institute
Orlando, Florida, 32804, United States
-
Fiona Stanley Hospital
Murdoch, Western Australia, 6150, Australia
-
Norton Cancer Institute - Saint Matthews
Louisville, Kentucky, 40207, United States
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania, 19107, United States
-
University of Virgina
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.